0.019455
0.000000
0.000000
0.000000
0.017036
0.000000
0.000000
0.000000
0.016129
0.00000
0.00000
0.00000
Wickramasinghe, W.
Begun, J.
Martin, J.L.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
8
90.00
90.00
90.00
51.400
58.700
62.000
C4 H9 N O2
103.120
n
ALPHA-AMINOBUTYRIC ACID
L-peptide linking
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
H2 O
18.015
WATER
non-polymer
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C33 H48 N4 O6
596.757
[1-BENZYL-3-(8-SEC-BUTYL-7,10-DIOXO-2-OXA-6,9-DIAZA-BICYCLO[11.2.2] HEPTADECA-1(16),13(17),14-TRIEN-11-YLAMINO)-2-HYDROXY-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER
MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 6
peptide-like
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
O4 S -2
96.063
SULFATE ION
non-polymer
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
J.Am.Chem.Soc.
JACSAT
0004
0002-7863
118
3375
3379
-1
Substrate-based cyclic peptidomimetics of Phe-Ile-Val that inhibit HIV-1 protease using a novel enzyme-binding mode.
1996
10.2210/pdb1mtr/pdb
pdb_00001mtr
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
289
1
IMAGE PLATE
1995-03-28
RIGAKU RAXIS IIC
M
x-ray
1
1.5418
1.0
1.5418
10765.687
HIV-1 PROTEASE
3.4.23.16
2
man
polymer
96.063
SULFATE ION
3
syn
non-polymer
596.757
[1-BENZYL-3-(8-SEC-BUTYL-7,10-DIOXO-2-OXA-6,9-DIAZA-BICYCLO[11.2.2] HEPTADECA-1(16),13(17),14-TRIEN-11-YLAMINO)-2-HYDROXY-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER
1
syn
non-polymer
18.015
water
115
nat
water
no
yes
PQITLWKRPLVTIRIGGQLKEALLDTGADDTVIEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPVEI(ABA)GHKAIGTVL
VGPTPVNIIGRNLLTQIG(ABA)TLNF
PQITLWKRPLVTIRIGGQLKEALLDTGADDTVIEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPVEIAGHKAIGTVLVGPT
PVNIIGRNLLTQIGATLNF
A,B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
Lentivirus
Escherichia
sample
11676
Human immunodeficiency virus 1
562
Escherichia coli
1
2.11
44.
5.5
pH 5.5
database_2
pdbx_database_status
struct_conn
struct_ref_seq_dif
struct_site
pdbx_initial_refinement_model
repository
Initial release
Version format compliance
Atomic model
Database references
Derived calculations
Non-polymer description
Structure summary
Version format compliance
Non-polymer description
Non-polymer description
Non-polymer description
Other
Database references
Derived calculations
Other
Refinement description
1
0
1996-08-01
1
1
2008-03-24
1
2
2011-07-13
1
3
2011-08-24
1
4
2012-07-25
1
5
2012-09-19
1
6
2012-12-12
1
7
2021-11-03
1
8
2023-08-09
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.process_site
_struct_conn.pdbx_leaving_atom_flag
_struct_conn.ptnr1_auth_comp_id
_struct_conn.ptnr1_auth_seq_id
_struct_conn.ptnr1_label_atom_id
_struct_conn.ptnr1_label_comp_id
_struct_conn.ptnr1_label_seq_id
_struct_conn.ptnr2_auth_comp_id
_struct_conn.ptnr2_auth_seq_id
_struct_conn.ptnr2_label_atom_id
_struct_conn.ptnr2_label_comp_id
_struct_conn.ptnr2_label_seq_id
_struct_ref_seq_dif.details
_struct_site.pdbx_auth_asym_id
_struct_site.pdbx_auth_comp_id
_struct_site.pdbx_auth_seq_id
Y
BNL
1996-02-15
REL
SO4
SULFATE ION
PI6
[1-BENZYL-3-(8-SEC-BUTYL-7,10-DIOXO-2-OXA-6,9-DIAZA-BICYCLO[11.2.2] HEPTADECA-1(16),13(17),14-TRIEN-11-YLAMINO)-2-HYDROXY-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER
HOH
water
GLN 7 WAS REPLACED BY LYS TO PREVENT AUTOCLEAVAGE.
LEU 33 WAS REPLACED BY ILE TO PREVENT AUTOCLEAVAGE.
CYS 67 WAS REPLACED BY ABA FOR EASE OF CHEMICAL
SYNTHESIS. CYS 95 WAS REPLACED BY ABA FOR EASE OF
CHEMICAL SYNTHESIS.
1CPI
PDB
experimental model
Inhibitor
tert-butyl [(1S,2S)-1-benzyl-2-hydroxy-3-{[(8S,11R)-8-[(1R)-1-methylpropyl]-7,10-dioxo-2-oxa-6,9-diazabicyclo[11.2.2]heptadeca-1(15),13,16-trien-11-yl]amino}propyl]carbamate
Peptide-like
SO4
502
2
SO4
SO4
101
A
SO4
503
2
SO4
SO4
102
A
PI6
100
3
PI6
PI6
101
B
SO4
501
2
SO4
SO4
102
B
HOH
302
4
HOH
HOH
201
A
HOH
306
4
HOH
HOH
202
A
HOH
307
4
HOH
HOH
203
A
HOH
311
4
HOH
HOH
204
A
HOH
312
4
HOH
HOH
205
A
HOH
313
4
HOH
HOH
206
A
HOH
314
4
HOH
HOH
207
A
HOH
318
4
HOH
HOH
208
A
HOH
319
4
HOH
HOH
209
A
HOH
327
4
HOH
HOH
210
A
HOH
329
4
HOH
HOH
211
A
HOH
332
4
HOH
HOH
212
A
HOH
333
4
HOH
HOH
213
A
HOH
334
4
HOH
HOH
214
A
HOH
335
4
HOH
HOH
215
A
HOH
339
4
HOH
HOH
216
A
HOH
341
4
HOH
HOH
217
A
HOH
342
4
HOH
HOH
218
A
HOH
344
4
HOH
HOH
219
A
HOH
345
4
HOH
HOH
220
A
HOH
346
4
HOH
HOH
221
A
HOH
349
4
HOH
HOH
222
A
HOH
351
4
HOH
HOH
223
A
HOH
353
4
HOH
HOH
224
A
HOH
362
4
HOH
HOH
225
A
HOH
374
4
HOH
HOH
226
A
HOH
375
4
HOH
HOH
227
A
HOH
376
4
HOH
HOH
228
A
HOH
377
4
HOH
HOH
229
A
HOH
378
4
HOH
HOH
230
A
HOH
380
4
HOH
HOH
231
A
HOH
381
4
HOH
HOH
232
A
HOH
382
4
HOH
HOH
233
A
HOH
383
4
HOH
HOH
234
A
HOH
384
4
HOH
HOH
235
A
HOH
385
4
HOH
HOH
236
A
HOH
388
4
HOH
HOH
237
A
HOH
389
4
HOH
HOH
238
A
HOH
390
4
HOH
HOH
239
A
HOH
391
4
HOH
HOH
240
A
HOH
393
4
HOH
HOH
241
A
HOH
394
4
HOH
HOH
242
A
HOH
396
4
HOH
HOH
243
A
HOH
399
4
HOH
HOH
244
A
HOH
400
4
HOH
HOH
245
A
HOH
403
4
HOH
HOH
246
A
HOH
405
4
HOH
HOH
247
A
HOH
406
4
HOH
HOH
248
A
HOH
409
4
HOH
HOH
249
A
HOH
411
4
HOH
HOH
250
A
HOH
414
4
HOH
HOH
251
A
HOH
415
4
HOH
HOH
252
A
HOH
416
4
HOH
HOH
253
A
HOH
301
4
HOH
HOH
301
B
HOH
303
4
HOH
HOH
302
B
HOH
304
4
HOH
HOH
303
B
HOH
305
4
HOH
HOH
304
B
HOH
308
4
HOH
HOH
305
B
HOH
309
4
HOH
HOH
306
B
HOH
310
4
HOH
HOH
307
B
HOH
315
4
HOH
HOH
308
B
HOH
316
4
HOH
HOH
309
B
HOH
317
4
HOH
HOH
310
B
HOH
320
4
HOH
HOH
311
B
HOH
321
4
HOH
HOH
312
B
HOH
322
4
HOH
HOH
313
B
HOH
323
4
HOH
HOH
314
B
HOH
324
4
HOH
HOH
315
B
HOH
325
4
HOH
HOH
316
B
HOH
326
4
HOH
HOH
317
B
HOH
328
4
HOH
HOH
318
B
HOH
330
4
HOH
HOH
319
B
HOH
331
4
HOH
HOH
320
B
HOH
336
4
HOH
HOH
321
B
HOH
337
4
HOH
HOH
322
B
HOH
338
4
HOH
HOH
323
B
HOH
340
4
HOH
HOH
324
B
HOH
343
4
HOH
HOH
325
B
HOH
347
4
HOH
HOH
326
B
HOH
348
4
HOH
HOH
327
B
HOH
350
4
HOH
HOH
328
B
HOH
352
4
HOH
HOH
329
B
HOH
354
4
HOH
HOH
330
B
HOH
355
4
HOH
HOH
331
B
HOH
356
4
HOH
HOH
332
B
HOH
357
4
HOH
HOH
333
B
HOH
358
4
HOH
HOH
334
B
HOH
359
4
HOH
HOH
335
B
HOH
360
4
HOH
HOH
336
B
HOH
361
4
HOH
HOH
337
B
HOH
363
4
HOH
HOH
338
B
HOH
364
4
HOH
HOH
339
B
HOH
365
4
HOH
HOH
340
B
HOH
366
4
HOH
HOH
341
B
HOH
367
4
HOH
HOH
342
B
HOH
368
4
HOH
HOH
343
B
HOH
369
4
HOH
HOH
344
B
HOH
370
4
HOH
HOH
345
B
HOH
371
4
HOH
HOH
346
B
HOH
372
4
HOH
HOH
347
B
HOH
373
4
HOH
HOH
348
B
HOH
379
4
HOH
HOH
349
B
HOH
386
4
HOH
HOH
350
B
HOH
387
4
HOH
HOH
351
B
HOH
392
4
HOH
HOH
352
B
HOH
395
4
HOH
HOH
353
B
HOH
397
4
HOH
HOH
354
B
HOH
398
4
HOH
HOH
355
B
HOH
401
4
HOH
HOH
356
B
HOH
402
4
HOH
HOH
357
B
HOH
404
4
HOH
HOH
358
B
HOH
407
4
HOH
HOH
359
B
HOH
408
4
HOH
HOH
360
B
HOH
410
4
HOH
HOH
361
B
HOH
413
4
HOH
HOH
362
B
PRO
1
n
1
PRO
1
A
GLN
2
n
2
GLN
2
A
ILE
3
n
3
ILE
3
A
THR
4
n
4
THR
4
A
LEU
5
n
5
LEU
5
A
TRP
6
n
6
TRP
6
A
LYS
7
n
7
LYS
7
A
ARG
8
n
8
ARG
8
A
PRO
9
n
9
PRO
9
A
LEU
10
n
10
LEU
10
A
VAL
11
n
11
VAL
11
A
THR
12
n
12
THR
12
A
ILE
13
n
13
ILE
13
A
ARG
14
n
14
ARG
14
A
ILE
15
n
15
ILE
15
A
GLY
16
n
16
GLY
16
A
GLY
17
n
17
GLY
17
A
GLN
18
n
18
GLN
18
A
LEU
19
n
19
LEU
19
A
LYS
20
n
20
LYS
20
A
GLU
21
n
21
GLU
21
A
ALA
22
n
22
ALA
22
A
LEU
23
n
23
LEU
23
A
LEU
24
n
24
LEU
24
A
ASP
25
n
25
ASP
25
A
THR
26
n
26
THR
26
A
GLY
27
n
27
GLY
27
A
ALA
28
n
28
ALA
28
A
ASP
29
n
29
ASP
29
A
ASP
30
n
30
ASP
30
A
THR
31
n
31
THR
31
A
VAL
32
n
32
VAL
32
A
ILE
33
n
33
ILE
33
A
GLU
34
n
34
GLU
34
A
GLU
35
n
35
GLU
35
A
MET
36
n
36
MET
36
A
ASN
37
n
37
ASN
37
A
LEU
38
n
38
LEU
38
A
PRO
39
n
39
PRO
39
A
GLY
40
n
40
GLY
40
A
LYS
41
n
41
LYS
41
A
TRP
42
n
42
TRP
42
A
LYS
43
n
43
LYS
43
A
PRO
44
n
44
PRO
44
A
LYS
45
n
45
LYS
45
A
MET
46
n
46
MET
46
A
ILE
47
n
47
ILE
47
A
GLY
48
n
48
GLY
48
A
GLY
49
n
49
GLY
49
A
ILE
50
n
50
ILE
50
A
GLY
51
n
51
GLY
51
A
GLY
52
n
52
GLY
52
A
PHE
53
n
53
PHE
53
A
ILE
54
n
54
ILE
54
A
LYS
55
n
55
LYS
55
A
VAL
56
n
56
VAL
56
A
ARG
57
n
57
ARG
57
A
GLN
58
n
58
GLN
58
A
TYR
59
n
59
TYR
59
A
ASP
60
n
60
ASP
60
A
GLN
61
n
61
GLN
61
A
ILE
62
n
62
ILE
62
A
PRO
63
n
63
PRO
63
A
VAL
64
n
64
VAL
64
A
GLU
65
n
65
GLU
65
A
ILE
66
n
66
ILE
66
A
ABA
67
n
67
ABA
67
A
GLY
68
n
68
GLY
68
A
HIS
69
n
69
HIS
69
A
LYS
70
n
70
LYS
70
A
ALA
71
n
71
ALA
71
A
ILE
72
n
72
ILE
72
A
GLY
73
n
73
GLY
73
A
THR
74
n
74
THR
74
A
VAL
75
n
75
VAL
75
A
LEU
76
n
76
LEU
76
A
VAL
77
n
77
VAL
77
A
GLY
78
n
78
GLY
78
A
PRO
79
n
79
PRO
79
A
THR
80
n
80
THR
80
A
PRO
81
n
81
PRO
81
A
VAL
82
n
82
VAL
82
A
ASN
83
n
83
ASN
83
A
ILE
84
n
84
ILE
84
A
ILE
85
n
85
ILE
85
A
GLY
86
n
86
GLY
86
A
ARG
87
n
87
ARG
87
A
ASN
88
n
88
ASN
88
A
LEU
89
n
89
LEU
89
A
LEU
90
n
90
LEU
90
A
THR
91
n
91
THR
91
A
GLN
92
n
92
GLN
92
A
ILE
93
n
93
ILE
93
A
GLY
94
n
94
GLY
94
A
ABA
95
n
95
ABA
95
A
THR
96
n
96
THR
96
A
LEU
97
n
97
LEU
97
A
ASN
98
n
98
ASN
98
A
PHE
99
n
99
PHE
99
A
PRO
1
n
1
PRO
1
B
GLN
2
n
2
GLN
2
B
ILE
3
n
3
ILE
3
B
THR
4
n
4
THR
4
B
LEU
5
n
5
LEU
5
B
TRP
6
n
6
TRP
6
B
LYS
7
n
7
LYS
7
B
ARG
8
n
8
ARG
8
B
PRO
9
n
9
PRO
9
B
LEU
10
n
10
LEU
10
B
VAL
11
n
11
VAL
11
B
THR
12
n
12
THR
12
B
ILE
13
n
13
ILE
13
B
ARG
14
n
14
ARG
14
B
ILE
15
n
15
ILE
15
B
GLY
16
n
16
GLY
16
B
GLY
17
n
17
GLY
17
B
GLN
18
n
18
GLN
18
B
LEU
19
n
19
LEU
19
B
LYS
20
n
20
LYS
20
B
GLU
21
n
21
GLU
21
B
ALA
22
n
22
ALA
22
B
LEU
23
n
23
LEU
23
B
LEU
24
n
24
LEU
24
B
ASP
25
n
25
ASP
25
B
THR
26
n
26
THR
26
B
GLY
27
n
27
GLY
27
B
ALA
28
n
28
ALA
28
B
ASP
29
n
29
ASP
29
B
ASP
30
n
30
ASP
30
B
THR
31
n
31
THR
31
B
VAL
32
n
32
VAL
32
B
ILE
33
n
33
ILE
33
B
GLU
34
n
34
GLU
34
B
GLU
35
n
35
GLU
35
B
MET
36
n
36
MET
36
B
ASN
37
n
37
ASN
37
B
LEU
38
n
38
LEU
38
B
PRO
39
n
39
PRO
39
B
GLY
40
n
40
GLY
40
B
LYS
41
n
41
LYS
41
B
TRP
42
n
42
TRP
42
B
LYS
43
n
43
LYS
43
B
PRO
44
n
44
PRO
44
B
LYS
45
n
45
LYS
45
B
MET
46
n
46
MET
46
B
ILE
47
n
47
ILE
47
B
GLY
48
n
48
GLY
48
B
GLY
49
n
49
GLY
49
B
ILE
50
n
50
ILE
50
B
GLY
51
n
51
GLY
51
B
GLY
52
n
52
GLY
52
B
PHE
53
n
53
PHE
53
B
ILE
54
n
54
ILE
54
B
LYS
55
n
55
LYS
55
B
VAL
56
n
56
VAL
56
B
ARG
57
n
57
ARG
57
B
GLN
58
n
58
GLN
58
B
TYR
59
n
59
TYR
59
B
ASP
60
n
60
ASP
60
B
GLN
61
n
61
GLN
61
B
ILE
62
n
62
ILE
62
B
PRO
63
n
63
PRO
63
B
VAL
64
n
64
VAL
64
B
GLU
65
n
65
GLU
65
B
ILE
66
n
66
ILE
66
B
ABA
67
n
67
ABA
67
B
GLY
68
n
68
GLY
68
B
HIS
69
n
69
HIS
69
B
LYS
70
n
70
LYS
70
B
ALA
71
n
71
ALA
71
B
ILE
72
n
72
ILE
72
B
GLY
73
n
73
GLY
73
B
THR
74
n
74
THR
74
B
VAL
75
n
75
VAL
75
B
LEU
76
n
76
LEU
76
B
VAL
77
n
77
VAL
77
B
GLY
78
n
78
GLY
78
B
PRO
79
n
79
PRO
79
B
THR
80
n
80
THR
80
B
PRO
81
n
81
PRO
81
B
VAL
82
n
82
VAL
82
B
ASN
83
n
83
ASN
83
B
ILE
84
n
84
ILE
84
B
ILE
85
n
85
ILE
85
B
GLY
86
n
86
GLY
86
B
ARG
87
n
87
ARG
87
B
ASN
88
n
88
ASN
88
B
LEU
89
n
89
LEU
89
B
LEU
90
n
90
LEU
90
B
THR
91
n
91
THR
91
B
GLN
92
n
92
GLN
92
B
ILE
93
n
93
ILE
93
B
GLY
94
n
94
GLY
94
B
ABA
95
n
95
ABA
95
B
THR
96
n
96
THR
96
B
LEU
97
n
97
LEU
97
B
ASN
98
n
98
ASN
98
B
PHE
99
n
99
PHE
99
B
author_and_software_defined_assembly
PISA
2
dimeric
5730
-58
9020
A
ABA
67
ALPHA-AMINOBUTYRIC ACID
A
ABA
67
ALA
A
ABA
95
ALPHA-AMINOBUTYRIC ACID
A
ABA
95
ALA
B
ABA
67
ALPHA-AMINOBUTYRIC ACID
B
ABA
67
ALA
B
ABA
95
ALPHA-AMINOBUTYRIC ACID
B
ABA
95
ALA
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
CG
LYS
41
A
CG
LYS
41
1
Y
1
A
CD
LYS
41
A
CD
LYS
41
1
Y
1
A
CE
LYS
41
A
CE
LYS
41
1
Y
1
A
NZ
LYS
41
A
NZ
LYS
41
1
Y
1
A
CG
LYS
43
A
CG
LYS
43
1
Y
1
A
CD
LYS
43
A
CD
LYS
43
1
Y
1
A
CE
LYS
43
A
CE
LYS
43
1
Y
1
A
NZ
LYS
43
A
NZ
LYS
43
1
Y
1
B
CG
LYS
41
B
CG
LYS
41
1
Y
1
B
CD
LYS
41
B
CD
LYS
41
1
Y
1
B
CE
LYS
41
B
CE
LYS
41
1
Y
1
B
NZ
LYS
41
B
NZ
LYS
41
1
Y
1
B
CG
LYS
43
B
CG
LYS
43
1
Y
1
B
CD
LYS
43
B
CD
LYS
43
1
Y
1
B
CE
LYS
43
B
CE
LYS
43
1
Y
1
B
NZ
LYS
43
B
NZ
LYS
43
1
Y
1
B
B
O
O
ILE
HOH
50
304
2.17
B
1
-8.81
1.40
111.50
102.69
B
B
B
CA
N
CD
PRO
PRO
PRO
1
1
1
N
1
B
GLU
35
-34.50
112.90
18.7
RESIDUES 50 AND 51 IN THE FLAP REGION OF BOTH SUBUNITS ARE DISORDERED AND WERE MODELLED IN TWO CONFORMATIONS. HOWEVER, THESE REGIONS OF THE STRUCTURE HAVE RELATIVELY POOR GEOMETRY.
0.244
0.179
0.179
1.75
8.0
1661
16283
10.
84.
1
2.0
DIFFERENCE FOURIER
1CPI
0.2
1.75
8.0
115
1673
58
0
1500
0.010
1.66
26.1
1.40
1.5
2.0
2.0
2.5
1.75
50.
1MTR
16528
1.
0.068
1
10.5
5.3
85.9
0.219
1.75
2.0
2.42
1
2.5
69.2
model building
X-PLOR
3.1
refinement
X-PLOR
3.1
data reduction
PROCESS
(HIGASHI/RIGAKU)
data scaling
PROCESS
phasing
X-PLOR
3.1
HIV-1 PROTEASE COMPLEXED WITH A CYCLIC PHE-ILE-VAL PEPTIDOMIMETIC INHIBITOR
1
N
N
1
N
N
2
N
N
2
N
N
3
N
N
2
N
N
4
N
N
4
N
N
A
GLY
86
A
GLY
86
HELX_P
A
GLY
94
A
GLY
94
1
HA
9
B
GLY
86
B
GLY
86
HELX_P
B
GLY
94
B
GLY
94
1
HB
9
covale
1.330
both
A
ILE
66
A
C
ILE
66
1_555
A
ABA
67
A
N
ABA
67
1_555
covale
1.325
both
A
ABA
67
A
C
ABA
67
1_555
A
GLY
68
A
N
GLY
68
1_555
covale
1.321
both
A
GLY
94
A
C
GLY
94
1_555
A
ABA
95
A
N
ABA
95
1_555
covale
1.328
both
A
ABA
95
A
C
ABA
95
1_555
A
THR
96
A
N
THR
96
1_555
covale
1.332
both
B
ILE
66
B
C
ILE
66
1_555
B
ABA
67
B
N
ABA
67
1_555
covale
1.331
both
B
ABA
67
B
C
ABA
67
1_555
B
GLY
68
B
N
GLY
68
1_555
covale
1.332
both
B
GLY
94
B
C
GLY
94
1_555
B
ABA
95
B
N
ABA
95
1_555
covale
1.328
both
B
ABA
95
B
C
ABA
95
1_555
B
THR
96
B
N
THR
96
1_555
HYDROLASE/HYDROLASE INHIBITOR
ASPARTYL PROTEINASE, AIDS, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR complex
POL_HV1A2
UNP
1
1
P03369
FFREDLAFLQGKAREFSSEQTRANSPTRRELQVWGGENNSLSEAGADRQGTVSFNFPQITLWQRPLVTIRIGGQLKEALL
DTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPI
ETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQ
DFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMT
KILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIM
LPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHEVYYDPSKDL
VAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKVSTESIVIWGKIPKFKLPIQKETWEAWWMEY
WQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKVVSIADTTNQKTELQAIHLA
LQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKVLFLNGI
DKAQEEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIE
AEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTSTTVKAACWWAGIKQEFGIPYNPQSQGVVESMNNELKKIIGQV
RDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDNKDPLWKGPAKLLWKG
EGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED
57
155
1MTR
1
99
P03369
A
1
1
99
57
155
1MTR
1
99
P03369
B
1
1
99
1
GLN
engineered mutation
LYS
7
1MTR
A
P03369
UNP
63
7
1
LEU
engineered mutation
ILE
33
1MTR
A
P03369
UNP
89
33
1
CYS
engineered mutation
ABA
67
1MTR
A
P03369
UNP
123
67
1
CYS
engineered mutation
ABA
95
1MTR
A
P03369
UNP
151
95
2
GLN
engineered mutation
LYS
7
1MTR
B
P03369
UNP
63
7
2
LEU
engineered mutation
ILE
33
1MTR
B
P03369
UNP
89
33
2
CYS
engineered mutation
ABA
67
1MTR
B
P03369
UNP
123
67
2
CYS
engineered mutation
ABA
95
1MTR
B
P03369
UNP
151
95
8
8
4
anti-parallel
anti-parallel
parallel
anti-parallel
parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
parallel
anti-parallel
parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
A
LYS
43
A
LYS
43
A
GLY
49
A
GLY
49
A
GLY
52
A
GLY
52
A
ILE
66
A
ILE
66
A
HIS
69
A
HIS
69
A
GLY
78
A
GLY
78
A
THR
31
A
THR
31
A
GLU
34
A
GLU
34
A
ASN
83
A
ASN
83
A
ILE
85
A
ILE
85
A
GLN
18
A
GLN
18
A
ASP
25
A
ASP
25
A
PRO
9
A
PRO
9
A
ILE
15
A
ILE
15
A
GLU
65
A
GLU
65
A
ILE
66
A
ILE
66
B
LYS
43
B
LYS
43
B
GLY
49
B
GLY
49
B
GLY
52
B
GLY
52
B
ILE
66
B
ILE
66
B
HIS
69
B
HIS
69
B
GLY
78
B
GLY
78
B
THR
31
B
THR
31
B
GLU
34
B
GLU
34
B
ASN
83
B
ASN
83
B
ILE
85
B
ILE
85
B
GLN
18
B
GLN
18
B
ASP
25
B
ASP
25
B
PRO
9
B
PRO
9
B
ILE
15
B
ILE
15
B
GLU
65
B
GLU
65
B
ILE
66
B
ILE
66
A
PRO
1
A
PRO
1
A
THR
4
A
THR
4
B
THR
96
B
THR
96
B
PHE
99
B
PHE
99
A
THR
96
A
THR
96
A
PHE
99
A
PHE
99
B
PRO
1
B
PRO
1
B
THR
4
B
THR
4
BINDING SITE FOR RESIDUE SO4 A 101
A
SO4
101
Software
2
BINDING SITE FOR RESIDUE SO4 A 102
A
SO4
102
Software
8
BINDING SITE FOR RESIDUE PI6 B 101
B
PI6
101
Software
19
BINDING SITE FOR RESIDUE SO4 B 102
B
SO4
102
Software
5
A
PRO
1
A
PRO
1
2
1_555
A
HIS
69
A
HIS
69
2
1_555
A
ARG
14
A
ARG
14
8
1_555
A
GLY
17
A
GLY
17
8
1_555
A
HOH
245
G
HOH
8
1_555
B
ARG
14
B
ARG
14
8
1_455
B
ILE
15
B
ILE
15
8
1_455
B
GLY
16
B
GLY
16
8
1_455
B
GLY
17
B
GLY
17
8
1_455
B
HOH
308
H
HOH
8
1_455
A
ARG
8
A
ARG
8
19
1_555
A
LEU
23
A
LEU
23
19
1_555
A
ASP
25
A
ASP
25
19
1_555
A
GLY
27
A
GLY
27
19
1_555
A
GLY
48
A
GLY
48
19
1_555
A
GLY
49
A
GLY
49
19
1_555
A
ILE
50
A
ILE
50
19
1_555
A
PRO
81
A
PRO
81
19
1_555
A
VAL
82
A
VAL
82
19
1_555
B
ARG
8
B
ARG
8
19
1_555
B
ASP
25
B
ASP
25
19
1_555
B
GLY
27
B
GLY
27
19
1_555
B
ALA
28
B
ALA
28
19
1_555
B
ASP
29
B
ASP
29
19
1_555
B
GLY
48
B
GLY
48
19
1_555
B
ILE
50
B
ILE
50
19
1_555
B
PRO
81
B
PRO
81
19
1_555
B
HOH
301
H
HOH
19
1_555
B
HOH
325
H
HOH
19
1_555
A
HIS
69
A
HIS
69
5
3_545
A
LYS
70
A
LYS
70
5
3_545
A
HOH
249
G
HOH
5
3_545
B
PRO
1
B
PRO
1
5
2_554
B
LYS
55
B
LYS
55
5
1_555
19
P 21 21 21